Molecular Pharmacology (USA) Limited (MLPH)
OTHER OTC:MLPH
MLPH Stock Chart & Stats
$0.02
<$0.01(9900.00%)
At close: 4:00 PM EST
$0.02
<$0.01(9900.00%)
Day’s Range― - ―
52-Week Range$0.02 - $0.02
Previous CloseN/A
Volume1.00K
Average Volume (3M)0.00
Market Cap
$199.91K
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta52.75
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding999,553,700
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
MLPH FAQ
What was Molecular Pharmacology (USA) Limited’s price range in the past 12 months?
Molecular Pharmacology (USA) Limited lowest stock price was $0.02 and its highest was $0.02 in the past 12 months.
What is Molecular Pharmacology (USA) Limited’s market cap?
Molecular Pharmacology (USA) Limited’s market cap is $199.91K.
When is Molecular Pharmacology (USA) Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Molecular Pharmacology (USA) Limited’s earnings last quarter?
Currently, no data Available
Is Molecular Pharmacology (USA) Limited overvalued?
According to Wall Street analysts Molecular Pharmacology (USA) Limited’s price is currently Overvalued.
Does Molecular Pharmacology (USA) Limited pay dividends?
Molecular Pharmacology (USA) Limited does not currently pay dividends.
What is Molecular Pharmacology (USA) Limited’s EPS estimate?
Molecular Pharmacology (USA) Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Molecular Pharmacology (USA) Limited have?
Molecular Pharmacology (USA) Limited has 999,553,700 shares outstanding.
What happened to Molecular Pharmacology (USA) Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Molecular Pharmacology (USA) Limited?
Currently, no hedge funds are holding shares in MLPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Molecular Pharmacology (USA) Limited
As a development-stage company, Molecular Pharmacology (USA) Limited (MLPH) is dedicated to the creation and market introduction of solutions for pain and inflammation, with a primary focus on the Australian and United States markets. Through its subsidiary, Molecular Pharmacology Pty. Ltd., it is advancing an analgesic and anti-inflammatory molecule called Tripeptofen, designed to alleviate common daily pain. These products are offered in diverse dosage forms, formulations, and packaging options to suit various needs. MLPH's marketing strategy involves leveraging pharmaceutical distributors and forging collaborative partnerships with companies in the United States and Europe. Additionally, the company maintains an agreement with Dermatology Development Corporation to jointly develop and market a suite of therapeutic, cosmetic, and cosmeceutical items derived from the ThermaLIFE product line and its core active component. Headquartered in Perth, Australia, Molecular Pharmacology (USA) Limited operates as a subsidiary of PharmaNet Group Limited.